Galderma's record H1 performance is partly fueled by a structural shift in patient demand: GLP-1 users seeking to address volume loss and skin laxity triggered by rapid weight reduction. The "Ozempic face" phenomenon—characterized by hollowing, jowling, and loss of skin elasticity—has become a clinical driver for both neuromodulators and volumizing fillers, as well as RF microneedling and biostimulator treatments.
Market
Galderma Capitalizes on GLP-1 Weight-Loss Trend—What Practices Need to Know
As patients on semaglutide and tirzepatide seek facial rejuvenation, Galderma's H1 surge reflects the medspa industry's pivot to post-GLP-1 aesthetics.
GLP-1 users seeking facial rejuvenation are driving demand for volumizers and biostimulators alongside neuromodulators.
This trend creates both opportunity and operational complexity for independent practices. Patients on GLP-1s often require higher filler volumes and more frequent touch-ups due to accelerated metabolism and altered facial anatomy. Practices should anticipate longer consultation times, revised treatment protocols, and potential inventory planning shifts. The uptick also explains why Galderma—with its breadth across Botox, Juvéderm, and Radiesse—is outpacing single-category competitors.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.